Recent ALZN News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 09:30:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 09:30:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 09:30:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/15/2023 09:30:30 PM
- Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients • Business Wire • 12/11/2023 01:00:00 PM
- Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients • Business Wire • 11/20/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 09:30:19 PM
- Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement • Business Wire • 11/16/2023 01:00:00 PM
- Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of Next‑Generation Lithium Therapeutic Drug Candidate AL001 • Business Wire • 11/13/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:30:17 PM
- Alzamend Neuro Announces Reverse Stock Split • Business Wire • 10/30/2023 12:00:00 PM
- Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next‑Generation Lithium Therapeutic Drug Candidate AL001 • Business Wire • 10/23/2023 12:00:00 PM
- Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients • Business Wire • 10/02/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/29/2023 08:30:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/26/2023 10:01:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/22/2023 08:30:19 PM
- Alzamend Neuro Granted Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing Requirement • Business Wire • 09/22/2023 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 09/13/2023 09:09:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 09/08/2023 09:05:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/08/2023 09:00:24 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 09/01/2023 08:30:10 PM
- Alzamend Neuro Submits IND Application for Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients • Business Wire • 08/30/2023 12:00:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/24/2023 08:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/16/2023 08:30:19 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/11/2023 04:15:07 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM